Acticor Biotech

Acticor Biotech is advancing a targeted therapeutic platform focused on inhibiting platelet glycoprotein VI (GPVI) to treat acute thrombotic diseases with a potentially superior safety profile. Its lead asset, glenzocimab, has demonstrated promising Phase 1b/2a results in acute ischemic stroke (AIS) and is progressing into a pivotal Phase 2/3 study (ACTISAVE), alongside a Phase 2 program in myocardial infarction. The company's strategy is to establish glenzocimab as a new standard of care adjuvant therapy, used alongside thrombolysis and thrombectomy, to improve recanalization and functional outcomes while minimizing bleeding risk.

Platform based on inhibition of platelet glycoprotein VI (GPVI) using a humanized monoclonal antibody fragment (Fab) to selectively block pathological thrombus formation while preserving normal hemostasis.

Glenzocimab is a first-in-class GPVI inhibitor with no direct approved competitors. It competes indirectly with standard antiplatelets avoided in acute stroke due to bleeding risk. Its primary advantage is a mechanism designed for efficacy in acute thrombosis with a potentially lower bleeding liability.